Hoth Therapeutics Files 8-K on Officer/Director Changes

TL;DR

Hoth Therapeutics 8-K: Leadership changes and other events reported August 20, 2025.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers other events and financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in corporate leadership can introduce uncertainty regarding future strategy and performance.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• August 20, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar
• $550,000 — ll (i) receive an annual base salary of $550,000, (ii) be eligible to receive an annual
• $550,000 b — ble to receive an annual bonus of up to $550,000 based upon the achievement of Company and

Filing Documents

• ea0254112-8k_hoth.htm (8-K) — 34KB
• ea025411201ex10-1_hoth.htm (EX-10.1) — 123KB
• 0001213900-25-079915.txt ( ) — 356KB
• hoth-20250820.xsd (EX-101.SCH) — 3KB
• hoth-20250820_lab.xml (EX-101.LAB) — 33KB
• hoth-20250820_pre.xml (EX-101.PRE) — 22KB
• ea0254112-8k_hoth_htm.xml (XML) — 4KB

02. Departure

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 21, 2025, the board of directors (the "Board of Directors") of Hoth Therapeutics, Inc. (the "Company") approved the entry into an employment agreement (the "Employment Agreement") with Robb Knie and on August 22, 2025 the Company entered into the Employment Agreement with Robb Knie pursuant to which Mr. Knie shall continue to serve as Chief Executive Officer and President of the Company. Unless terminated earlier pursuant to its terms, the Employment Agreement shall commence on the Effective Date and shall continue until the third anniversary of the Effective Date and thereafter shall automatically renew for successive one year terms unless either party provides written notice of non-renewal to the other party at least six months prior to the last day of the then-current term. Pursuant to the Employment Agreement, Mr. Knie shall (i) receive an annual base salary of $550,000, (ii) be eligible to receive an annual bonus of up to $550,000 based upon the achievement of Company and individual performance targets established by the Company's compensation committee, (iii) be eligible to receive equity incentive and (iv) be entitled to participate in any benefit plans offered by the Company (the "Benefit Plans"). Furthermore, the Company will cover Mr. Knie under directors' and officers' liability insurance during his employment and for a period of six years following the termination of his employment. In addition, if during the term of the Employment Agreement (and so long as Mr. Knie is employed by the Company on the closing date of the Transaction (as defined below)), the Company enters into a Transaction, Mr. Knie will be eligible to receive a one-time bonus (the "Transaction Bonus"), based on the Equity Value (as defined in the Employment Agreement) of the Company measured as of the closing date of suc

01 Other Events

Item 8.01 Other Events On August 20, 2025, the Company filed a Patent Cooperation Treaty patent application with the United States Patent and Trademark Office for HT-001, its topical formulation for treating side effects from drugs used for the treatment of cancer, claiming priority to US provisional application nos. 63/750,577 and 63/685,456.

01 Financial

Item 9.01 Financial (d) Exhibits. Exhibit No. Description 10.1+ Employment Agreement by and between the Company and Robb Knie dated August 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Indicates a management contract or any compensatory plan, contract or arrangement. -2-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 22, 2025 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR